Autopsy report · NCT03420963
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Cause of deathSlow enrollment
“\<75% participation”
Life of this trial
- Registered 7 months before it started.
- Ran for about 7 years 6 months before it stopped.
- 12 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Recurrent Cutaneous Melanoma; Recurrent Lip and Oral Cavity Carcinoma; Recurrent Malignant Endocrine Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Male Reproductive System Neoplasm; Recurrent Malignant Mesothelioma
- Interventions
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells; Cyclophosphamide; Etoposide
- Participants
- 12
- Sites
- 1
- Countries
- United States
Trials that died the same way
- ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
“\<75% participants” - Vapocoolant Analgesia for Breast Lymphoscintigraphy
“\<75% accrued participants” - Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery
“low participation rate” - Physiotherapy and Therapeutic Education After Total Knee Arthroplasty.
“low participation” - Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
“Lack of participations (8 of 25)”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.